Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 113

1.

The antibody targeting the E314 peptide of human Kv1.3 pore region serves as a novel, potent and specific channel blocker.

Yang XF, Yang Y, Lian YT, Wang ZH, Li XW, Cheng LX, Liu JP, Wang YF, Gao X, Liao YH, Wang M, Zeng QT, Liu K.

PLoS One. 2012;7(4):e36379. doi: 10.1371/journal.pone.0036379.

2.

Specific Kv1.3 blockade modulates key cholesterol-metabolism-associated molecules in human macrophages exposed to ox-LDL.

Yang Y, Wang YF, Yang XF, Wang ZH, Lian YT, Yang Y, Li XW, Gao X, Chen J, Shu YW, Cheng LX, Liao YH, Liu K.

J Lipid Res. 2013 Jan;54(1):34-43. doi: 10.1194/jlr.M023846.

3.

Margatoxin is a non-selective inhibitor of human Kv1.3 K+ channels.

Bartok A, Toth A, Somodi S, Szanto TG, Hajdu P, Panyi G, Varga Z.

Toxicon. 2014 Sep;87:6-16. doi: 10.1016/j.toxicon.2014.05.002.

PMID:
24878374
4.

Interaction of propofol with voltage-gated human Kv1.5 channel through specific amino acids within the pore region.

Kojima A, Ito Y, Ding WG, Kitagawa H, Matsuura H.

Eur J Pharmacol. 2015 Oct 5;764:622-32. doi: 10.1016/j.ejphar.2015.08.007.

PMID:
26256861
5.

The membrane permeable calcium chelator BAPTA-AM directly blocks human ether a-go-go-related gene potassium channels stably expressed in HEK 293 cells.

Tang Q, Jin MW, Xiang JZ, Dong MQ, Sun HY, Lau CP, Li GR.

Biochem Pharmacol. 2007 Dec 3;74(11):1596-607.

PMID:
17826747
6.

Curcumin serves as a human kv1.3 blocker to inhibit effector memory T lymphocyte activities.

Lian YT, Yang XF, Wang ZH, Yang Y, Yang Y, Shu YW, Cheng LX, Liu K.

Phytother Res. 2013 Sep;27(9):1321-7. doi: 10.1002/ptr.4863.

PMID:
23132777
7.

Inhibitory actions of the phosphatidylinositol 3-kinase inhibitor LY294002 on the human Kv1.5 channel.

Wu J, Ding WG, Matsuura H, Tsuji K, Zang WJ, Horie M.

Br J Pharmacol. 2009 Jan;156(2):377-87. doi: 10.1111/j.1476-5381.2008.00017.x.

8.

Intravenous anesthetic propofol inhibits multiple human cardiac potassium channels.

Yang L, Liu H, Sun HY, Li GR.

Anesthesiology. 2015 Mar;122(3):571-84. doi: 10.1097/ALN.0000000000000495.

PMID:
25321870
9.

Tst26, a novel peptide blocker of Kv1.2 and Kv1.3 channels from the venom of Tityus stigmurus.

Papp F, Batista CV, Varga Z, Herceg M, Román-González SA, Gaspar R, Possani LD, Panyi G.

Toxicon. 2009 Sep 15;54(4):379-89. doi: 10.1016/j.toxicon.2009.05.023.

PMID:
19500613
10.

N-Terminally extended analogues of the K⁺ channel toxin from Stichodactyla helianthus as potent and selective blockers of the voltage-gated potassium channel Kv1.3.

Chang SC, Huq R, Chhabra S, Beeton C, Pennington MW, Smith BJ, Norton RS.

FEBS J. 2015 Jun;282(12):2247-59. doi: 10.1111/febs.13294.

11.

Acacetin causes a frequency- and use-dependent blockade of hKv1.5 channels by binding to the S6 domain.

Wu HJ, Wu W, Sun HY, Qin GW, Wang HB, Wang P, Yalamanchili HK, Wang J, Tse HF, Lau CP, Vanhoutte PM, Li GR.

J Mol Cell Cardiol. 2011 Dec;51(6):966-73. doi: 10.1016/j.yjmcc.2011.08.022.

PMID:
21906601
12.

The effects of ginsenoside Rg(3) on human Kv1.4 channel currents without the N-terminal rapid inactivation domain.

Lee JH, Choi SH, Lee BH, Shin TJ, Pyo MK, Hwang SH, Kim BR, Lee SM, Bae DH, Rhim H, Nah SY.

Biol Pharm Bull. 2009 Apr;32(4):614-8.

13.

Mapping of maurotoxin binding sites on hKv1.2, hKv1.3, and hIKCa1 channels.

Visan V, Fajloun Z, Sabatier JM, Grissmer S.

Mol Pharmacol. 2004 Nov;66(5):1103-12.

14.

Characterization of a novel Kv1.5 channel blocker in Xenopus oocytes, CHO cells, human and rat cardiomyocytes.

Bachmann A, Gutcher I, Kopp K, Brendel J, Bosch RF, Busch AE, Gögelein H.

Naunyn Schmiedebergs Arch Pharmacol. 2001 Nov;364(5):472-8.

PMID:
11692231
15.
16.

Characterization of the functional properties of the voltage-gated potassium channel Kv1.3 in human CD4+ T lymphocytes.

Hu L, Pennington M, Jiang Q, Whartenby KA, Calabresi PA.

J Immunol. 2007 Oct 1;179(7):4563-70.

17.

Anuroctoxin, a new scorpion toxin of the alpha-KTx 6 subfamily, is highly selective for Kv1.3 over IKCa1 ion channels of human T lymphocytes.

Bagdány M, Batista CV, Valdez-Cruz NA, Somodi S, Rodriguez de la Vega RC, Licea AF, Varga Z, Gáspár R, Possani LD, Panyi G.

Mol Pharmacol. 2005 Apr;67(4):1034-44.

18.

Inhibitory effect of bepridil on hKv1.5 channel current: comparison with amiodarone and E-4031.

Kobayashi S, Reien Y, Ogura T, Saito T, Masuda Y, Nakaya H.

Eur J Pharmacol. 2001 Nov 2;430(2-3):149-57.

PMID:
11711026
19.

Novel, potent inhibitors of human Kv1.5 K+ channels and ultrarapidly activating delayed rectifier potassium current.

Lagrutta A, Wang J, Fermini B, Salata JJ.

J Pharmacol Exp Ther. 2006 Jun;317(3):1054-63.

20.

Targeting effector memory T cells with a selective peptide inhibitor of Kv1.3 channels for therapy of autoimmune diseases.

Beeton C, Pennington MW, Wulff H, Singh S, Nugent D, Crossley G, Khaytin I, Calabresi PA, Chen CY, Gutman GA, Chandy KG.

Mol Pharmacol. 2005 Apr;67(4):1369-81.

Supplemental Content

Support Center